Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Novartis Investigative Site, Nanjing, Jiangsu, China

Novartis Investigative Site, Beijing, China

Novartis Investigative Site, Beijing, China

Novartis Investigative Site, Shanghai, China

Novartis Investigative Site, Bordeaux, France

Novartis Investigative Site, Paris, France

Novartis Investigative Site, Paris, France

Novartis Investigative Site, Rouen, France

Novartis Investigative Site, Toulouse, France

Novartis Investigative Site, Tours, France

Novartis Investigative Site, Essen, Germany

Novartis Investigative Site, Kiel, Germany

Novartis Investigative Site, Ranica, BG, Italy

Novartis Investigative Site, Milan, MI, Italy

Novartis Investigative Site, Roma, RM, Italy

Novartis Investigative Site, Matsumoto-shi, Nagano, Japan

Novartis Investigative Site, Iruma-gun, Saitama, Japan

Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan

Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

Novartis Investigative Site, Barcelona, Spain

Novartis Investigative Site, Córdoba, Spain

Novartis Investigative Site, Málaga, Spain

Novartis Investigative Site, Seville, Spain

Novartis Investigative Site, Valencia, Spain

Novartis Investigative Site, Izmir, Balcova, Turkey (Türkiye)

Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)

Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

Novartis Investigative Site, Mersin, Yenisehir, Turkey (Türkiye)

Novartis Investigative Site, Glasgow, Scotland, United Kingdom

Novartis Investigative Site, Newcastle upon Tyne, Tyne and Wear, United Kingdom

Novartis Investigative Site, London, United Kingdom